MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for cannabinoid receptors and that has been sold online as a designer drug. The structure of MDMB-FUBINACA contains the npAA L-tert-Leucine. MDMB-FUBINACA has Ki values of 1.14nM at CB1 and 0.1228nM at CB2 and EC50 values of 0.2668nM at CB1 and 0.1411nM at CB2.
Side effects There have been a large number of reported cases of deaths and hospitalizations in relation to this chemical, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold by 2015. Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and a subsequent published study confirmed that at least 1000 hospitalizations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015.
Legal status
In the United States, MDMB-FUBINACA is a Schedule I controlled substance.
As of October 2015, MDMB-FUBINACA is a controlled substance in Belarus, Russia, and China.
In July 2021, it was included in Table II-A in the list of prohibited drugs of Portugal.
See also
5F-AB-PINACA 5F-ADB 5F-AMB 5F-APINACA AB-FUBINACA AB-CHFUPYCA AB-CHMINACA AB-PINACA ADB-BINACA ADB-CHMINACA ADB-FUBINACA ADB-PINACA ADBICA APICA APINACA APP-FUBINACA MDMB-CHMICA MDMB-CHMINACA PX-3 VIP36
References